1. Clinical & Scientific Overview
Vincristine Sulfate (TIP-MED-000563, Reference Code [ONC-14]) is classified under
Oncology & Antineoplastic Medicines as a Vinca Alkaloid (M-Phase Specific) • Vinca Alkaloid Microtubule Polymerisation Inhibitor.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Oncovin Reference, Cytocristin (Cipla Ltd), Biocristin (Biochem)
Solution for IV Injection: 1 mg/mL (1 mL and 2 mL vials)
Oncology Specialisation & Cytotoxic Safety Protocol
Vinca Alkaloid (M-Phase Specific)
Antineoplastic Cytotoxic (Vesicant)
Standard Regimen & Cycle Context: 1.4 mg/m2 IV push/mini-bag on Day 1 of cycle — UNIVERSAL ADULT SINGLE-DOSE CAP: MAXIMUM 2.0 mg TOTAL DOSE to prevent crippling neurotoxicity.
Signature Dose-Limiting Toxicities & Organ Monitoring: FATAL IF GIVEN INTRATHECALLY (100% lethal ascending radiculomyeloencephalopathy); Dose-limiting Axonal Sensorimotor and Autonomic Neuropathy (loss of Achilles ankle jerk reflex is earliest sign, followed by foot drop, wrist drop, cranial nerve palsies, and severe paralytic ileus/constipation) and SIADH.
Extravasation, Premedication & Safe Cytotoxic Handling: ISMP HIGH-ALERT SAFEGUARD: Dispense Vincristine ONLY in a 25–50 mL mini-bag of 0.9% NaCl (never in a syringe that could be mistaken for an intrathecal syringe) labelled 'FOR INTRAVENOUS USE ONLY — FATAL IF GIVEN BY OTHER ROUTES'; prescribe prophylactic stimulant + osmotic laxative (senna + lactulose) to prevent autonomic paralytic ileus.
3. Mechanism of Action & Pharmacodynamics
Binds the vinca domain on beta-tubulin dimers, preventing polymerisation into microtubules and dissolving the mitotic spindle during metaphase.
4. Therapeutic Indications & Evidence-Supported Uses
- Acute Lymphoblastic Leukaemia (ALL)
- Non-Hodgkin Lymphoma (R-CHOP regimen)
- Wilms tumour, Rhabdomyosarcoma, and Neuroblastoma
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): 1.4 mg/m2 IV push/mini-bag on Day 1 of cycle — UNIVERSAL ADULT SINGLE-DOSE CAP: MAXIMUM 2.0 mg TOTAL DOSE to prevent crippling neurotoxicity.
Administration & Meal Timing: 1.4 mg/m2 IV push/mini-bag on Day 1 of cycle — UNIVERSAL ADULT SINGLE-DOSE CAP: MAXIMUM 2.0 mg TOTAL DOSE to prevent crippling neurotoxicity.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Vincristine or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: FATAL IF GIVEN INTRATHECALLY (100% lethal ascending radiculomyeloencephalopathy); Dose-limiting Axonal Sensorimotor and Autonomic Neuropathy (loss of Achilles ankle jerk reflex is earliest sign, followed by foot drop, wrist drop, cranial nerve palsies, and severe paralytic ileus/constipation) and SIADH.
8. Adverse Effects Profile
- FATAL IF GIVEN INTRATHECALLY (100% lethal ascending radiculomyeloencephalopathy); Dose-limiting Axonal Sensorimotor and Autonomic Neuropathy (loss of Achilles ankle jerk reflex is earliest sign, followed by foot drop, wrist drop, cranial nerve palsies, and severe paralytic ileus/constipation) and SIADH.
- FATAL IF GIVEN INTRATHECALLY (100% lethal ascending radiculomyeloencephalopathy); Dose-limiting Axonal Sensorimotor and Autonomic Neuropathy (loss of Achilles ankle jerk reflex is earliest sign, followed by foot drop, wrist drop, cranial nerve palsies, and severe paralytic ileus/constipation) and SIADH.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- FATAL IF GIVEN INTRATHECALLY (100% lethal ascending radiculomyeloencephalopathy); Dose-limiting Axonal Sensorimotor and Autonomic Neuropathy (loss of Achilles ankle jerk reflex is earliest sign, followed by foot drop, wrist drop, cranial nerve palsies, and severe paralytic ileus/constipation) and SIADH.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: ISMP HIGH-ALERT SAFEGUARD: Dispense Vincristine ONLY in a 25–50 mL mini-bag of 0.9% NaCl (never in a syringe that could be mistaken for an intrathecal syringe) labelled 'FOR INTRAVENOUS USE ONLY — FATAL IF GIVEN BY OTHER ROUTES'; prescribe prophylactic stimulant + osmotic laxative (senna + lactulose) to prevent autonomic paralytic ileus.
Pharmacist Patient Counselling Points:
- ISMP HIGH-ALERT SAFEGUARD: Dispense Vincristine ONLY in a 25–50 mL mini-bag of 0.9% NaCl (never in a syringe that could be mistaken for an intrathecal syringe) labelled 'FOR INTRAVENOUS USE ONLY — FATAL IF GIVEN BY OTHER ROUTES'; prescribe prophylactic stimulant + osmotic laxative (senna + lactulose) to prevent autonomic paralytic ileus.
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: ISMP HIGH-ALERT SAFEGUARD: Dispense Vincristine ONLY in a 25–50 mL mini-bag of 0.9% NaCl (never in a syringe that could be mistaken for an intrathecal syringe) labelled 'FOR INTRAVENOUS USE ONLY — FATAL IF GIVEN BY OTHER ROUTES'; prescribe prophylactic stimulant + osmotic laxative (senna + lactulose) to prevent autonomic paralytic ileus.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.